Teva Puerto Rico LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

Phase 3

Completed

Conditions: Hormone Replacement Therapy

Interventions: Drug: Estradiol acetate
Drug: Estradiol
Drug: Conjugated equine estrogens

First Posted Date: 2010-02-18

Last Posted Date: 2013-04-22

Lead Sponsor: Warner Chilcott

Target Recruit Count: 249

Registration Number: NCT01070979

Locations: 🇺🇸
Warner Chilcott Investigational Site, Tacoma, Washington, United States

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

Phase 3

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Udenafil 150 mg
Drug: Udenafil 50 mg
Drug: Udenafil 100 mg
Drug: Placebo Matching 100 mg Udenafil
Drug: Placebo Matching 50 mg Udenafil
Drug: Placebo Matching 150 mg Udenafil

First Posted Date: 2010-02-09

Last Posted Date: 2015-04-20

Lead Sponsor: Warner Chilcott

Target Recruit Count: 1027

Registration Number: NCT01065012

Locations: 🇺🇸
Warner Chilcott Investigational Site, Spokane, Washington, United States
🇺🇸
Warner Chilcott Investigative Site, Wilmington, North Carolina, United States

Treatment of Erectile Dysfunction I

Phase 3

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Placebo
Drug: Udenafil

First Posted Date: 2009-12-22

Last Posted Date: 2011-12-22

Lead Sponsor: Warner Chilcott

Target Recruit Count: 618

Registration Number: NCT01037244

Locations: 🇺🇸
Warner Chilcott Investigational Site, Spokane, Washington, United States

Treatment of Erectile Dysfunction II

Phase 3

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Udenafil
Drug: Placebo

First Posted Date: 2009-12-22

Last Posted Date: 2015-06-19

Lead Sponsor: Warner Chilcott

Target Recruit Count: 601

Registration Number: NCT01037218

Locations: 🇺🇸
Warner Chilcott Investigational Site, Mountlake Terrace, Washington, United States

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

Phase 3

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Asacol 400 mg

First Posted Date: 2009-10-29

Last Posted Date: 2012-05-25

Lead Sponsor: Warner Chilcott

Target Recruit Count: 39

Registration Number: NCT01004185

Locations: 🇷🇺
Research Site, Smolensk, Russian Federation

Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

Phase 2

Terminated

Conditions: Heart Failure

Interventions: Drug: placebo
Drug: testosterone

First Posted Date: 2009-08-12

Last Posted Date: 2012-01-13

Lead Sponsor: Warner Chilcott

Target Recruit Count: 17

Registration Number: NCT00957034

Locations: 🇺🇸
Research Site, Tacoma, Washington, United States

Study of Safety and Efficacy of an Oral Contraceptive

Phase 3

Completed

Conditions: Prevention of Pregnancy

Interventions: Drug: Norethindrone Acetate/Ethinyl Estradiol 24 Days
Drug: Norethindrone Acetate /Ethinyl Estradiol 21 Days

First Posted Date: 2009-07-03

Last Posted Date: 2013-04-22

Lead Sponsor: Warner Chilcott

Target Recruit Count: 938

Registration Number: NCT00932321

Locations: 🇺🇸
Warner Chilcott Investigational Site, Seattle, Washington, United States

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Phase 2

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: 150 mg
Drug: 100 mg
Drug: 75 mg

First Posted Date: 2009-06-11

Last Posted Date: 2015-06-29

Lead Sponsor: Warner Chilcott

Target Recruit Count: 205

Registration Number: NCT00918749

Locations: 🇺🇸
Research Site, Dallas, Texas, United States

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 35 mg risedronate DR tablet

First Posted Date: 2009-03-25

Last Posted Date: 2011-10-12

Lead Sponsor: Warner Chilcott

Target Recruit Count: 101

Registration Number: NCT00868907

Locations: 🇺🇸
Research Site, Evansville, Indiana, United States

A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Osteoporosis

Interventions: Drug: risedronate DR (Phase III clinical supply)
Drug: risedronate 35 mg DR (Commercial Tablet)

First Posted Date: 2009-02-18

Last Posted Date: 2011-10-12

Lead Sponsor: Warner Chilcott

Target Recruit Count: 538

Registration Number: NCT00846196

Locations: 🇺🇸
Research site, Austin, Texas, United States
🇺🇸
Research Site, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy